Literature DB >> 30225218

Frequency of IL-10-producing regulatory B cells associated with disease activity in thyroid-associated orbitopathy.

Yun-Gang Ding1,2, Guo Chen1, Qian Li1,3, Xiao-Feng Wen1, Lai Wei1, Hua-Sheng Yang1.   

Abstract

AIM: To investigate the association between IL-10-producing regulatory B (B10) cells and the clinical features of thyroid-associated orbitopathy (TAO).
METHODS: A total of 30 patients with TAO were recruited at Zhongshan Ophthalmic Center from May 2015 to December 2015. Peripheral blood mononuclear cells (PBMCs) were separated from blood samples of 30 TAO patients and 16 healthy controls and stimulated with CD40 ligand and CpG for 48h. The frequency of IL-10+ B cells was examined by flow cytometry and the correlation between the frequency of IL-10+ B cells and clinical features of TAO was analyzed by SPSS.
RESULTS: The frequency of IL-10+ B cells among CD19+ B cells in TAO patients was significantly lower than in healthy controls (TAO: 4.66%±1.88% vs healthy control: 6.82%±2.40%, P<0.01). The frequency of IL-10+ B cells showed a positive correlation with disease activity of TAO measured by Clinical Activity Score (CAS) (r=0.50, P<0.01), and became higher in TAO patients with family history of Graves' disease (GD) (P=0.04).
CONCLUSION: The decrease of the frequency of IL-10+ B cells in TAO patients indicates the deficiency of B10 cells in TAO, and the positive association with disease activity suggests its important role in TAO inflammation regulation.

Entities:  

Keywords:  flow cytometry; interleukin-10; regulatory B cells; thyroid-associated orbitopathy

Year:  2018        PMID: 30225218      PMCID: PMC6133891          DOI: 10.18240/ijo.2018.09.05

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  29 in total

Review 1.  Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.

Authors:  Laszlo Hegedüs; Terry J Smith; Raymond S Douglas; Claus H Nielsen
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

2.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

Authors:  M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

3.  Modification of the classification of the eye changes of Graves' disease.

Authors:  S C Werner
Journal:  Am J Ophthalmol       Date:  1977-05       Impact factor: 5.258

4.  The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder.

Authors:  Yuan Sun; Ying Huang; Wei-Wei Chen; Juan Jia; Tao Wei
Journal:  Neurol Sci       Date:  2018-03-03       Impact factor: 3.307

5.  Allergen-specific transforming growth factor-β-producing CD19+CD5+ regulatory B-cell (Br3) responses in human late eczematous allergic reactions to cow's milk.

Authors:  Jae Ho Lee; Joonyong Noh; Geunwoong Noh; Wahn Soo Choi; Sunheui Cho; Sang Sun Lee
Journal:  J Interferon Cytokine Res       Date:  2011-02-03       Impact factor: 2.607

6.  A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses.

Authors:  Koichi Yanaba; Jean-David Bouaziz; Karen M Haas; Jonathan C Poe; Manabu Fujimoto; Thomas F Tedder
Journal:  Immunity       Date:  2008-05       Impact factor: 31.745

7.  Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach.

Authors:  M P Mourits; L Koornneef; W M Wiersinga; M F Prummel; A Berghout; R van der Gaag
Journal:  Br J Ophthalmol       Date:  1989-08       Impact factor: 4.638

8.  CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.

Authors:  Paul A Blair; Lina Yassin Noreña; Fabian Flores-Borja; David J Rawlings; David A Isenberg; Michael R Ehrenstein; Claudia Mauri
Journal:  Immunity       Date:  2010-01-14       Impact factor: 31.745

Review 9.  Diagnostic criteria for Graves' ophthalmopathy.

Authors:  G B Bartley; C A Gorman
Journal:  Am J Ophthalmol       Date:  1995-06       Impact factor: 5.258

10.  Prevention of arthritis by interleukin 10-producing B cells.

Authors:  Claudia Mauri; David Gray; Naseem Mushtaq; Marco Londei
Journal:  J Exp Med       Date:  2003-02-17       Impact factor: 14.307

View more
  1 in total

Review 1.  Advances of Regulatory B Cells in Autoimmune Diseases.

Authors:  Qiugang Zhu; Ke Rui; Shengjun Wang; Jie Tian
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.